{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:14:20Z","timestamp":1791476060736,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012435","name":"Project of High-level Teachers in Beijing Municipal Universities in the Period of 13th Five-year Plan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012435","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82374445"],"award-info":[{"award-number":["82374445"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82074427"],"award-info":[{"award-number":["82074427"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82305233"],"award-info":[{"award-number":["82305233"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014137","name":"Shanghai Shenkang Hospital Development Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014137","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.heliyon.2025.e42084","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T19:29:37Z","timestamp":1738092577000},"page":"e42084","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of Janus kinase inhibitors in the treatment of psoriasis and psoriatic arthritis: An analysis of evidence from 2014 to 2022"],"prefix":"10.1016","volume":"11","author":[{"given":"Jiao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seokgyeong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijung","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiale","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naixuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2525-9679","authenticated-orcid":false,"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2025.e42084_bib1","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.18296","article-title":"Global prevalence of metabolic syndrome in patients with psoriasis in the past two decades: current evidence","author":"Liu","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.heliyon.2025.e42084_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.759276","article-title":"Sphingosine-1-Phosphate and its signal modulators alleviate psoriasis-like dermatitis: preclinical and clinical evidence and possible mechanisms","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2025.e42084_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2017.05.019","article-title":"Psoriasis and suicidality: a systematic review and meta-analysis","volume":"77","author":"Singh","year":"2017","journal-title":"JAAD"},{"key":"10.1016\/j.heliyon.2025.e42084_bib4","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.heliyon.2025.e42084_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.670398","article-title":"Adverse events associated with anti-IL-23 agents: clinical evidence and possible mechanisms","volume":"12","author":"Ru","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2025.e42084_bib6","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors","volume":"398","author":"McLornan","year":"2021","journal-title":"Lancet."},{"key":"10.1016\/j.heliyon.2025.e42084_bib7","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis","volume":"158","author":"Olivera","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.heliyon.2025.e42084_bib8","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s40265-017-0835-9","article-title":"Tofacitinib: a review in rheumatoid arthritis","volume":"77","author":"Dhillon","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.heliyon.2025.e42084_bib9","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood-2013-03-484642","article-title":"The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo","volume":"122","author":"Heine","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2025.e42084_bib10","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40257-022-00684-1","article-title":"Baricitinib: a review in moderate to severe atopic dermatitis","volume":"23","author":"Hoy","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.heliyon.2025.e42084_bib11","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s40265-020-01439-0","article-title":"Filgotinib: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.heliyon.2025.e42084_bib12","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1124\/dmd.122.000829","article-title":"The pharmacokinetics, metabolism, and clearance mechanisms of abrocitinib, a selective janus kinase inhibitor, in humans","volume":"50","author":"Bauman","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.heliyon.2025.e42084_bib13","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1007\/s40265-021-01638-3","article-title":"Abrocitinib: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.heliyon.2025.e42084_bib14","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1158\/1078-0432.CCR-20-1739","article-title":"Itacitinib (INCB039110), a JAK1 inhibitor, reduces cytokines associated with cytokine release syndrome induced by CAR T-cell therapy","volume":"26","author":"Huarte","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2025.e42084_bib15","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1111\/jdv.18263","article-title":"The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - a network meta-analysis","volume":"36","author":"Zhang","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.heliyon.2025.e42084_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12895-016-0051-4","article-title":"Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial","volume":"16","author":"Papp","year":"2016","journal-title":"BMC Dermatol."},{"key":"10.1016\/j.heliyon.2025.e42084_bib17","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/bjd.13745","article-title":"A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis","volume":"173","author":"Papp","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.heliyon.2025.e42084_bib18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjd.12266","article-title":"A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis","volume":"169","author":"Ports","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.heliyon.2025.e42084_bib19","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/jdv.12081","article-title":"Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis","volume":"28","author":"Mamolo","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"6","key":"10.1016\/j.heliyon.2025.e42084_bib20","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.jaad.2016.07.040","article-title":"Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis","volume":"75","author":"Feldman","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.heliyon.2025.e42084_bib21","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/bjd.14403","article-title":"A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis","volume":"174","author":"Papp","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.heliyon.2025.e42084_bib22","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jaad.2011.12.018","article-title":"Preliminary clinical activity of a topical JAK1\/2 inhibitor in the treatment of psoriasis","volume":"67","author":"Punwani","year":"2012","journal-title":"JAAD"},{"key":"10.1016\/j.heliyon.2025.e42084_bib23","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3109\/09546634.2015.1115819","article-title":"A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis","volume":"27","author":"Bissonnette","year":"2016","journal-title":"J. Dermatol. Treat."},{"key":"10.1016\/j.heliyon.2025.e42084_bib24","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/bjd.14399","article-title":"Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study","volume":"174","author":"Ludbrook","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.heliyon.2025.e42084_bib25","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bjd.16004","article-title":"Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study","volume":"179","author":"Schmieder","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.heliyon.2025.e42084_bib26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jdermsci.2017.05.004","article-title":"The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: a Phase 3, randomized, double-blind, placebo-controlled study","volume":"88","author":"Zhang","year":"2017","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.heliyon.2025.e42084_bib27","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jaad.2016.01.013","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study","volume":"74","author":"Papp","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.heliyon.2025.e42084_bib28","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2025.e42084_bib29","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2025.e42084_bib30","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/rheumatology\/kez408","article-title":"Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR)","volume":"59","author":"Orbai","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.heliyon.2025.e42084_bib31","article-title":"Safety and efficacy of tofacitinib vs methotrexate in the treatment of psoriatic arthritis","author":"Sharma, S","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.heliyon.2025.e42084_bib32","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.heliyon.2025.e42084_bib33","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/bjd.12049","article-title":"STAT1 expression and activation is increased in lesional psoriatic skin","volume":"168","author":"Hald","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.heliyon.2025.e42084_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19010171","article-title":"Psoriasis: a STAT3-centric view","volume":"19","author":"Calautti","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2025.e42084_bib35","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/annrheumdis-2014-207201","article-title":"Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors","volume":"75","author":"Gao","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.heliyon.2025.e42084_bib36","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/283617","article-title":"JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis","volume":"2014","author":"Hsu","year":"2014","journal-title":"J Immunol Res"},{"key":"10.1016\/j.heliyon.2025.e42084_bib37","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdv.15489","article-title":"JAK inhibitors for alopecia areata: a systematic review and meta-analysis","volume":"33","author":"Phan","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.heliyon.2025.e42084_bib38","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1159\/000518541","article-title":"Efficacy and safety of janus kinase inhibitors for the treatment of atopic dermatitis: a systematic review and meta-analysis","volume":"238","author":"Li","year":"2022","journal-title":"Dermatology"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844025004645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844025004645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T12:56:36Z","timestamp":1775739396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844025004645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2405844025004645"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2025.e42084","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of Janus kinase inhibitors in the treatment of psoriasis and psoriatic arthritis: An analysis of evidence from 2014 to 2022","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2025.e42084","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e42084"}}